Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression
RH Howland, MG Wilson, SG Kornstein… - Annals of Clinical …, 2008 - Taylor & Francis
Background: To identify putative demographic and clinical variables that correlate with
antidepressant response to the SNRI duloxetine in major depression. Methods: The effect of …
antidepressant response to the SNRI duloxetine in major depression. Methods: The effect of …
An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for …
A Kuga, T Tsuji, S Hayashi, S Fujikoshi… - Neuropsychiatric …, 2017 - Taylor & Francis
Objective To examine how clinical and demographic patient baseline characteristics
influence effectiveness of duloxetine versus selective serotonin reuptake inhibitor (SSRI) …
influence effectiveness of duloxetine versus selective serotonin reuptake inhibitor (SSRI) …
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)
CH Mallinckrodt, A Prakash, JP Houston… - …, 2008 - karger.com
Objective: To test the hypothesis that in patients with major depressive disorder (MDD), the
response for specific Hamilton Depression Rating Scale items will differ for duloxetine …
response for specific Hamilton Depression Rating Scale items will differ for duloxetine …
Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses
R Gueorguieva, C Mallinckrodt… - Archives of general …, 2011 - jamanetwork.com
Context The high percentage of failed clinical trials in depression may be due to high
placebo response rates and the failure of standard statistical approaches to capture …
placebo response rates and the failure of standard statistical approaches to capture …
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo-and paroxetine-controlled trial
MJ Detke, CG Wiltse, CH Mallinckrodt… - European …, 2004 - Elsevier
Background: Duloxetine is a balanced and potent dual reuptake inhibitor of serotonin (5-HT)
and norepinephrine (NE) that has previously been shown to be effective in the acute …
and norepinephrine (NE) that has previously been shown to be effective in the acute …
Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder
DG Perahia, DK Kajdasz, D Desaiah… - Journal of affective …, 2005 - Elsevier
BACKGROUND: Discontinuation symptoms are common following antidepressant treatment.
This report characterizes symptoms following duloxetine discontinuation. METHODS: Data …
This report characterizes symptoms following duloxetine discontinuation. METHODS: Data …
Anxiety does not predict response to duloxetine in major depression: Results of a pooled analysis of individual patient data from 11 placebo‐controlled trials
JC Nelson - Depression and Anxiety, 2010 - Wiley Online Library
Background: Uncontrolled antidepressant trials suggest that anxious patients with major
depressive disorder (MDD) are less responsive to antidepressant treatment than less …
depressive disorder (MDD) are less responsive to antidepressant treatment than less …
The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study
M Fava, JM Martinez, J Greist… - Annals of Clinical …, 2007 - Taylor & Francis
Background. This study compares the efficacy and tolerability of 12 weeks of open-label
duloxetine in adult outpatients with anxious versus non-anxious depression. Methods …
duloxetine in adult outpatients with anxious versus non-anxious depression. Methods …
Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range
CH Mallinckrodt, A Prakash, AC Andorn… - Journal of psychiatric …, 2006 - Elsevier
OBJECTIVE: This analysis focuses on efficacy and safety data obtained from studies of
duloxetine for the treatment of major depressive disorder (MDD) within the approved dose …
duloxetine for the treatment of major depressive disorder (MDD) within the approved dose …
Dose–response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder
P Bech, DK Kajdasz, V Porsdal - Psychopharmacology, 2006 - Springer
Rationale The optimal dose for achieving the maximum antidepressive effect of selective
serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenalin reuptake inhibitors (SNRIs) …
serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenalin reuptake inhibitors (SNRIs) …